MOLECULAR PHARMACOLOGY

EDITOR: RAYMOND J. DINGLEDINE, *Emory University*

ASSOCIATE EDITORS: P. JEFFREY CONN, *Emory University*
MICHAEL M. GOTTESMAN, *National Institutes of Health*
BRIAN K. KOBILKA, *Stanford University*
KENNETH P. MINNEMAN, *Emory University*
EDWARD T. MORGAN, *Emory University*

MANAGING EDITOR: WENDY M. WILEY

EDITORIAL ASSISTANT: ESMERALDA GALÁN

About the cover: Depiction of cross-sectioned stereo views of the 5-HT_{2A} receptor complexes with ergonovine (*cyan*) and ergotamine (*red*). The helical backbones for transmembrane domains 3, 4, 6, and 7 are shown in *yellow*. A mutagenesis strategy was used to demonstrate the importance of receptor residues F340 and D155 (shown in *gray*) for docking with the ergoline nucleus. From Choudhary, M. S., N. Sachs, A. Uluer, R. A. Glennon, R. B. Westkaemper, and B. L. Roth. Different ergoline and ergopeptine binding to 5-hydroxytryptamine$_{2A}$ receptors: Ergolines require an aromatic residue at position 340 for high affinity binding. *Mol. Pharmacol.* **47**:450–457 (1995).